Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile
Adam Feuerstein ✡️

@adamfeuerstein

Biotech reporter @statnews. Dog ❤️er. Polk Award winner. #COYS. Said one analyst: The likes of Adam Feuerstein attack viciously. On Signal: stataf.54

ID: 102094857

linkhttp://www.statnews.com calendar_today05-01-2010 15:58:41

81,81K Tweet

117,117K Followers

757 Following

Michelle Solly (@msollender) 's Twitter Profile Photo

$MREO $RARE Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis globenewswire.com/news-release/2…

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

$SLNO pre-announced $31-33M in Vykat XR sales for Q2. Consensus was $8.1M per Visible Alpha. I assume buyside whisper expectations were much higher, but that's a very healthy start to the commercial launch. Consensus 2025 sales is $52M. SLNO also said 646 patient start forms

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

Wait.. BIG caveat. These CRL letters are for drugs that were later approved. The really good stuff -- CRLs for drugs not/never approved are not being disclosed.

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

If Makary is serious about drug-review transparency, publish CRLs when they're issued. That will be the true test. Disclosing old CRLs on drugs that were later approved doesn't tell you very much. Will it incentivize companies today to be more transparent and honest about

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

Doh... $SLNO preview of Q2 Vykart sales was my lead item in this week's Biotech Scorecard newsletter, but I did not see the company's preannouncement this morning before the newsletter was delivered. Apologies! Still, $SLNO Vykart launch is fast, strong out of the gate, and

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

$CAPR - FDA rejected deramiocel, citing "BLA does not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data." Company will unblind results of the Ph3 study and resubmit. capricor.com/investors/news…

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

FDA rejecting $CAPR deramiocel follows STAT reporting last month... The ouster of the FDA’s chief regulator of cell and gene therapies earlier this week came immediately after a disagreement with her boss over the review of a cell therapy for Duchenne muscular dystrophy, STAT

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

FDA rejects Capricor’s $CAPR cell therapy for Duchenne muscular dystrophy The FDA decision follows the ouster of the agency’s chief regulator of cell and gene therapies statnews.com/2025/07/11/fda…

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

Today's $CVM Saudi announcement, besides being hilarious, reminds of its fake South African partnership with the fictitious "Byron Biopharma" circa 2011. thestreet.com/investing/stoc…

Adam Feuerstein ✡️ (@adamfeuerstein) 's Twitter Profile Photo

HUGE STAT event announcement: Bill Gates in an exclusive live conversation with Matthew Herper Aug. 4 at the Broad in Kendall Sq. Free tickets: statnews.com/event/womens-h…